Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7860431 | 0.88 | XDH (0.54) | XDH | |
| SCHEMBL5404259 | 0.88 | XDH (0.63) | XDH | |
| SCHEMBL7865140 | 0.86 | XDH (0.54) | XDH | |
| SCHEMBL6052323 | 0.80 | XDH (0.47) | XDH | |
| SCHEMBL7860451 | 0.79 | ALDH1A1 (0.56) | XDH | |
| SCHEMBL440021 | 0.77 | XDH (1.00) | XDH | |
| SCHEMBL29693309 | 0.77 | XDH (1.00) | XDH | |
| SCHEMBL7861833 | 0.75 | XDH (0.46) | XDH | |
| SCHEMBL7060089 | 0.74 | XDH (0.47) | XDH | |
| SCHEMBL30267865 | 0.74 | XDH (0.63) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0936217-B1 | 1-PHENYLPYRAZOLE COMPOUNDS AND MEDICINAL APPLICATION THEREOF | WELFIDE CORP (JP) | 2001-11-07 | — | — | EP | claimed |
| US-6015829-A | 1-phenylpyrazole compounds and medicinal application thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-01-18 | — | — | US | claimed |
| US-7208514-B2 | Tumorigenesis inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20060106036-A1 | Tumorigenesis inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1609479-A1 | TUMORIGENESIS INHIBITOR | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-0936217-B1 | 1-PHENYLPYRAZOLE COMPOUNDS AND MEDICINAL APPLICATION THEREOF | WELFIDE CORP (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-6015829-A | 1-phenylpyrazole compounds and medicinal application thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| EP-0936217-A1 | 1-PHENYLPYRAZOLE COMPOUNDS AND MEDICINAL APPLICATION THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106036-A1 | Tumorigenesis inhibitor | XDH, LOXL1, LOX | XDH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.